Full text

 

 

J. Venom. Anim. Toxins incl. Trop. Dis.

V.19, p.225-231, 2013.

Short communication - ISSN 1678-9199.

 

Decrease in hepatitis B prevalence among blood donors in Central-West Brazil

 
AndrĂ©a de Siqueira Campos Lindenberg I, Ana Rita Coimbra Motta-Castro II, Marco Antonio Puga I, Tayana Serpa Ortiz Tanaka I, Marina Sawada Torres II, Sonia Maria Fernandes-Fitts I*, Rivaldo Venancio Cunha I

IFederal University of Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul State, Brazil

IIMato Grosso do Sul Hematology Center, Campo Grande, Mato Grosso do Sul State, Brazil

ABSTRACT

 

Background

The aim of the present study was to estimate hepatitis B virus seroprevalence among first-time blood donors in the city of Campo Grande, Mato Grosso do Sul State, in the central-western region of Brazil.

 

Findings

A retrospective analysis of first-time voluntary blood donor records, from January 2010 to December 2010, was conducted at the Hematology Center of Mato Grosso do Sul. The prevalence of the HBsAg and anti-HBc serological markers and their respective 95% confidence intervals were calculated. Chi-square analysis was performed between the seroprevalence previously found in 2001 and the one determined by the current study. Results were considered statistically significant if p < 0.05. Among 8,840 subjects, 269 (3.04%, 95% CI: 2.7-3.4) were positive for HBV markers. The prevalence rate of HBsAg was 0.19% (95% CI: 0.1-0.3) and anti-HBc alone was 2.85% (95% CI: 2.5-3.2).

 

Conclusions

There was no statistically significant difference regarding gender. However, an important association was observed between HBV infection and older age ( p < 0.01). The seroprevalence of HBV infection in first-time blood donors diminished from 2001 to 2010 ( p < 0.01). Such decrease suggests an improvement in the recruitment of safe donors, the positive impact of vaccination programs and the decreasing of HBV infection prevalence in the general population.

 

Key words: Hepatitis B virus; Prevalence; Blood donors

 

Ethics committee approval The present study was approved by the Ethics Committee of the Federal University of Mato Grosso do Sul (n. 1721/2010)

 

Received: September 4, 2012; Accepted: December 4, 2012

 

Competing interest The author declares no conflicts of interest.

 

Authors’ contributions ASCL, ARCMC, SMFF and RVC designed the study. MAP and TSOT did most of the laboratory work. MST, SMFF and ASCL provided and checked the clinical data for patients. ASCL, ARCMC and SMFF wrote the manuscript. All authors reviewed the draft and approved the final version.

 

Correspondence: sonia.fernandes@ufms.br